PMPRB
PMPRB
The PMPRB Asks: is the price excessive compared to other countries?
Regulatory: The PMPRB regulates and reports the price patented medications. Prices must be within limits set by the PMPRB if patented.
If price is found to be excessive, the PMPRB will hold public hearings and order price reductions and/or the offset of excess revenue.
Reporting: the PMPRB reports on pharmaceutical trends of all medicine and on the research and development spending by pharmaceutical patentees.
In essence, the PMPRB is in charge of ensuring that manufacturers with patented medications to not price their products excessively. They base their opinion of what an acceptable price is on the prices of drugs in other countries. There have been a lot of changes in the PMPRB Guidelines as of late, so be aware that many changes are likely to occur in the near future.
HDAP
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Category I
High cost: treatment cost > 150% GDP/capita, or High market size: market size (sales) > $50M
Category II
Patented medicines not in category I
-
VCU -
Hearing -
Closure
